Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
GermanyIPO:
07 November 2019Website:
http://www.centogene.comNext earnings report:
06 September 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 77 min agoDividend
Analysts recommendations
Institutional Ownership
CNTG Latest News
TUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path), a leader in forming collaborations that accelerate drug development, and Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, are pleased to announce the signing of a Memorandum of Understanding (MOU) to advance drug development for lysosomal diseases (LDs) and improve the quality of life for those impacted by these conditions.
Shares of Centogene NV CNTG, +8.31% gained 7% premarket on Friday after the company announced data confirming the utility of its proprietary biomarker lyso-Gb1 in indicating the severity of Gaucher disease, a rare inherited disorder that affects the body's ability to break down a certain type of fat. The study results also indicate that lyso-Gb1 could help predict the clinical course of patients and personalize care for the disease, Centogene said in a release.
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 05, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for May 2023. CENTOGENE representatives are attending events in Brazil, the U.S., and Germany, as well as virtually, and will be available to discuss Pharma, CRO, and Diagnostic collaboration opportunities. The Company invites attendees to schedule one-on-one meetings in advance.
What type of business is Centogene NV?
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including PCR and antigen testing services. It has collaboration and license agreements with Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.
What sector is Centogene NV in?
Centogene NV is in the Healthcare sector
What industry is Centogene NV in?
Centogene NV is in the Diagnostics & Research industry
What country is Centogene NV from?
Centogene NV is headquartered in Germany
When did Centogene NV go public?
Centogene NV initial public offering (IPO) was on 07 November 2019
What is Centogene NV website?
https://www.centogene.com
Is Centogene NV in the S&P 500?
No, Centogene NV is not included in the S&P 500 index
Is Centogene NV in the NASDAQ 100?
No, Centogene NV is not included in the NASDAQ 100 index
Is Centogene NV in the Dow Jones?
No, Centogene NV is not included in the Dow Jones index
When does Centogene NV report earnings?
The next expected earnings date for Centogene NV is 06 September 2024